Education
About Us
Working with TipRanks
Follow Us
Novartis Ag (NVS)
NYSE:NVS
Earnings Data
Report Date
Jul 17, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
2.31Last Year’s EPS
1.97Same Quarter Last Year
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -3.70%
|Next Earnings Date:Jul 17, 2025
Earnings Call Sentiment|Positive
Novartis reported a strong start to the year with significant sales growth and product approvals, leading to an upgraded full-year guidance. However, challenges remain in the rollout of Pluvicto and the impact of tariffs and European pricing. The sentiment is generally positive, but with some concerns over operational hurdles and geopolitical factors.Company Guidance
During the Novartis Q1 2025 earnings call, the company provided robust financial guidance, highlighting a strong start to the year with double-digit sales growth and significant margin expansion. Sales increased by 15%, while core operating income rose by 27%, resulting in a core margin of 42.1%. The company upgraded its full-year 2025 guidance, with expectations of sales growing high single digits and core operating income increasing at a low double-digit rate. Several key brands demonstrated impressive growth, with Kisqali sales up 56% and Kesimpta sales up 43% in constant currency. Additionally, Novartis achieved approvals for Pluvicto, Vanrafia, and Fabhalta, and made a global submission for remibrutinib. The company is also progressing in its gene therapy efforts, with a positive readout for OAV-101 IT for SMA, enhancing its strong pipeline momentum.Strong Financial Performance
Novartis delivered double-digit sales growth with a 15% increase in sales and a 27% rise in core operating income. The core margin reached 42.1%, a 400 basis point increase, resulting in an upgrade to the full-year 2025 guidance.
Key Product Growth
Kisqali grew 56% in constant currency, showing strong performance in both metastatic and early breast cancer. Kesimpta grew 43% in constant currency, outpacing the B cell and MS market. Pluvicto saw a 21% increase, with significant developments in its launch preparations.
Innovation and Approvals
Novartis achieved approvals for Pluvicto, Vanrafia, and Fabhalta, and had a positive readout for OAV-101 in SMA patients older than 2 years. A global submission was made for remibrutinib in CSU.
Upgraded Full-Year Guidance
Due to strong business momentum, Novartis raised its full-year guidance to high single-digit sales growth and low double-digit core operating income growth.
---
NVS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NVS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $112.63 | $113.45 | +0.73% |
Jan 31, 2025 | $101.67 | $101.64 | -0.03% |
Oct 29, 2024 | $112.23 | $107.28 | -4.41% |
Jul 18, 2024 | $108.51 | $104.06 | -4.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novartis Ag (NVS) report earnings?
Novartis Ag (NVS) is schdueled to report earning on Jul 17, 2025, TBA Not Confirmed.
What is Novartis Ag (NVS) earnings time?
Novartis Ag (NVS) earnings time is at Jul 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVS EPS forecast?
NVS EPS forecast for the fiscal quarter 2025 (Q2) is 2.31.
---
